Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?
Author:
Funder
NIH/NCI
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://link.springer.com/content/pdf/10.1186/s13046-019-1362-1.pdf
Reference175 articles.
1. Wheatley SP, Altieri DC. Survivin at a glance. J Cell Sci. 2019;132(7).
2. Li F. Discovery of Survivin Inhibitors and Beyond: FL118 as a Proof of Concept. Int Rev Cell Mol Biol. 2013;305:217–52.
3. Suzuki S, Yamamoto M, Sanomachi T, Togashi K, Sugai A, Seino S, et al. Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction. Cancers (Basel). 2019;11(7).
4. Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell. 2005;7(5):457–68.
5. Gyurkocza B, Plescia J, Raskett CM, Garlick DS, Lowry PA, Carter BZ, et al. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst. 2006;98(15):1068–77.
Cited by 151 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Overview of role of survivin in cancer: expression, regulation, functions, and its potential as a therapeutic target;Journal of Drug Targeting;2024-01-22
2. DNA-Based Nonviral Gene Therapy─Challenging but Promising;Molecular Pharmaceutics;2024-01-10
3. BIRC5 facilitates cisplatin‐chemoresistance in a m6A‐dependent manner in ovarian cancer;Cancer Medicine;2023-12-19
4. Structure–Activity Relationship of FL118 Platform Position 7 Versus Position 9-Derived Compounds and Their Mechanism of Action and Antitumor Activity;Journal of Medicinal Chemistry;2023-12-15
5. Small Molecule Inhibitors Targeting the “Undruggable” Survivin: The Past, Present, and Future from a Medicinal Chemist’s Perspective;Journal of Medicinal Chemistry;2023-12-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3